{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:50:46Z","timestamp":1784055046822,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.critrevonc.2026.105147","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:14:49Z","timestamp":1769184889000},"page":"105147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["NRG1 fusions\uff1aThe potential targeted treatment in non-small cell lung cancer(NSCLC)"],"prefix":"10.1016","volume":"219","author":[{"given":"Jiantao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.critrevonc.2026.105147_bib1","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105147_bib2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40265-025-02155-3","article-title":"Zenocutuzumab: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105147_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1634\/theoncologist.2020-0379","article-title":"Therapeutic potential of afatinib inNRG1Fusion-driven solid tumors: a case series","volume":"26","author":"Cadranel","year":"2021","journal-title":"Oncologist"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105147_bib4","article-title":"CRESTONE: initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions","volume":"40","author":"Carrizosa","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105147_bib5","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4143\/crt.2023.682","article-title":"Clinicopathological characteristics of NRG1 fusion\u2013positive solid tumors in Korean patients","volume":"55","author":"Cha","year":"2023","journal-title":"Cancer Res. Treat."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105147_bib6","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-21-0423","article-title":"Comprehensive molecular and clinicopathologic analysis of 200 pulmonary invasive mucinous adenocarcinomas identifies distinct characteristics of molecular subtypes","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105147_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102824","article-title":"Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: bridging biological insights and therapeutic development","volume":"130","author":"Corvaja","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105147_bib8","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1200\/JCO.20.03307","article-title":"Clinicopathologic features and response to therapy ofNRG1Fusion\u2013driven lung cancers: the eNRGy1 global multicenter registry","volume":"39","author":"Drilon","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105147_bib9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1158\/2159-8290.CD-17-1004","article-title":"Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105147_bib10","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1002\/cam4.838","article-title":"NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma","volume":"5","author":"Duruisseaux","year":"2016","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105147_bib11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0014-4827(02)00102-7","article-title":"Neuregulins: functions, forms, and signaling strategies","volume":"284","author":"Falls","year":"2003","journal-title":"Exp. Cell Res."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105147_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70191","article-title":"Clinical relevance and druggability of sole reciprocal kinase fusions: a large-scale study","volume":"13","author":"Feng","year":"2024","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105147_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1158\/2159-8290.CD-13-0633","article-title":"CD74\u2013NRG1 fusions in lung adenocarcinoma","volume":"4","author":"Fernandez-Cuesta","year":"2014","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105147_bib14","doi-asserted-by":"crossref","first-page":"e1844","DOI":"10.1002\/onco.13860","article-title":"A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors","volume":"26","author":"Gan","year":"2021","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105147_bib15","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.pathol.2024.02.014","article-title":"Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practice","volume":"56","author":"Garinet","year":"2024","journal-title":"Pathology"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105147_bib16","article-title":"Phase Ia\/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data","volume":"42","author":"Heymach","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105147_bib17","article-title":"Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report","volume":"42","author":"Illini","year":"2024","journal-title":"Cancer Treat. Res. Commun."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105147_bib18","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1158\/1078-0432.CCR-19-0160","article-title":"Detection of NRG1 gene fusions in solid tumors","volume":"25","author":"Jonna","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105147_bib19","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2217\/fon-2023-0824","article-title":"The phase I\/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions","volume":"20","author":"Kim","year":"2024","journal-title":"Future Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105147_bib20","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.annonc.2020.08.2335","article-title":"NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents","volume":"31","author":"Laskin","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105147_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2021.05.011","article-title":"NRG1 fusions: biology to therapy","volume":"158","author":"Liu","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105147_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107469","article-title":"Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions","volume":"188","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105147_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.2294","article-title":"LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1\/ERBB gene fusions","volume":"31","author":"Liu","year":"2020","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105147_bib24","article-title":"eNRGy: Making progress toward a future for NRG1 fusion-positive cancer","volume":"6","author":"Muscarella","year":"2025","journal-title":"Med (N. Y. N. Y. )"},{"key":"10.1016\/j.critrevonc.2026.105147_bib25","article-title":"A bispecific antibody delivers new treatment for NRG1 fusion-positive cancers","author":"O'Leary","year":"2025","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105147_bib26","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1158\/1078-0432.CCR-20-3605","article-title":"The Anti-HER3 mAb seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions","volume":"27","author":"Odintsov","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105147_bib27","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.jtho.2019.07.022","article-title":"Detection of Novel NRG1, EGFR, and MET fusions in lung adenocarcinomas in the chinese population","volume":"14","author":"Pan","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105147_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104545","article-title":"Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study","volume":"10","author":"Rodon","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105147_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-025-01005-1","article-title":"Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours","author":"Romero","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105147_bib30","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/sj.onc.1201317","article-title":"Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175","volume":"15","author":"Schaefer","year":"1997","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105147_bib31","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance","volume":"14","author":"Schram","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105147_bib32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 Fusion\u2013Positive Cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105147_bib33","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1634\/theoncologist.2018-0695","article-title":"Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer","volume":"24","author":"Sequist","year":"2019","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105147_bib34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jmoldx.2023.03.011","article-title":"RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers","volume":"25","author":"Severson","year":"2023","journal-title":"J. Mol. Diagn."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105147_bib35","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer Journal Clinicians"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105147_bib36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"38","key":"10.1016\/j.critrevonc.2026.105147_bib37","doi-asserted-by":"crossref","DOI":"10.2174\/0929867324666170911170554","article-title":"NRG1-ErbB Lost in Translation: a new paradigm for Lung Cancer?","volume":"24","author":"Trombetta","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105147_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115224","article-title":"Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: a prospective study","volume":"217","author":"Wang","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105147_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/s13000-023-01424-7","article-title":"Fluorescent in situ hybridization has limitations in screening NRG1 gene rearrangements","volume":"19","author":"Zhang","year":"2024","journal-title":"Diagn. Pathol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600034X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600034X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:24:32Z","timestamp":1770899072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600034X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"alternative-id":["S104084282600034X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105147","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NRG1 fusions\uff1aThe potential targeted treatment in non-small cell lung cancer(NSCLC)","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105147"}}